CORECIVIC, INC. financials

CXW CIK 0001070985

Source: EDGAR filings · Built 2026-06-02T02:47:39Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 52.16M 198.12M 163.56M 69.56M 181.18M 195.50M
EBITDA 313.52M
Working Capital 242.21M 164.02M 177.46M 62.92M 286.42M 403.72M
Net Debt 1.26B 910.88M 1.08B 1.24B 1.40B 1.86B
Operating Margin 8.54%
Net Margin 5.27% 3.51% 3.56% 6.63% -2.79% 2.84%
Return on Equity (ROE) 8.29% 4.61% 4.57% 8.54% -3.78% 3.90%
Return on Assets (ROA) 3.58% 2.35% 2.18% 3.77% -1.48% 1.46%
Current Ratio 1.66× 1.57× 1.60× 1.14× 1.84× 2.29×
Debt-to-Equity 0.96× 0.68× 0.81× 0.97× 1.24× 1.42×
Effective Tax Rate 25.88% 25.11% 29.46% 26.00% 160.27% 7.34%
Cash Conversion Ratio 1.67× 3.91× 3.43× 1.26× -5.07× 6.56×
Accruals Ratio -0.02× -0.07× -0.05× -0.01× -0.09× -0.08×
SBC % of Revenue 1.25% 1.31% 1.09% 0.95% 1.01% 0.91%
CapEx Coverage 1.37× 3.79× 3.39× 1.83× 3.21× 2.22×
Free Cash Flow Per Share $0.49 $1.79 $1.44 $0.59 $1.51 $1.62

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 17.69× 35.06× 24.63× 11.22× 14.56×
P/FCF 39.22× 12.17× 10.11× 19.64× 6.61× 4.05×
FCF Yield 2.55% 8.21% 9.89% 5.09% 15.12% 24.68%
EV / EBITDA 8.44×
P/S 0.86× 1.22× 0.86× 0.72× 0.64× 0.41×
P/B 1.36× 1.60× 1.11× 0.93× 0.87× 0.56×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenues 2.21B 1.96B 1.90B 1.85B 1.86B 1.91B
Operating Income (Loss) 162.66M
Income Tax Expense (Benefit) 40.67M 23.09M 28.23M 42.98M 138.00M 4.39M
Net Income (Loss) Attributable to Parent 122.32M -51.90M 54.16M
Earnings Per Share, Basic $1.09 $0.62 $0.59 $1.03 $-0.43 $0.45
Weighted Average Number of Shares Outstanding, Basic 107.03M 110.94M 113.80M 118.20M 120.19M 119.56M
Earnings Per Share, Diluted $1.08 $0.62 $0.59 $1.03 $-0.43 $0.45
Weighted Average Number of Shares Outstanding, Diluted 107.03M 110.94M 113.80M 118.20M 120.19M 120.93M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 97.93M 107.49M 121.84M 149.40M 299.64M 113.22M
Assets, Current 611.09M 449.82M 474.91M 513.67M 627.38M 717.12M
Assets 3.26B 2.93B 3.11B 3.24B 3.50B 3.71B
Liabilities, Current 368.87M 285.80M 297.45M 450.75M 340.97M 313.40M
Long-term Debt, Excluding Current Maturities 1.21B 973.07M 1.08B 1.08B 1.49B 1.75B
Liabilities 1.85B 1.44B 1.63B 1.81B 2.13B 2.30B
Stockholders' Equity Attributable to Parent 1.41B 1.49B 1.48B 1.43B 1.37B 1.39B
Common Stock, Shares, Outstanding 100.05M 109.86M 112.73M 114.99M 120.28M 119.64M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 194.59M 269.15M 231.90M 153.58M 263.23M 355.53M
Net Cash Provided by (Used in) Investing Activities -206.08M -53.82M -58.87M 73.04M 238.42M 12.97M
Payments for Repurchase of Common Stock 228.99M 77.17M 43.05M 79.89M 1.64M 3.58M
Payments of Dividends 45.00K 136.00K 131.00K 886.00K 2.51M 105.98M
Net Cash Provided by (Used in) Financing Activities 1.82M -222.18M -206.24M -375.16M -327.71M -350.82M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (CXW CIK 0001070985), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

GALT

GALECTIN THERAPEUTICS INC.

PLSE

Pulse Biosciences, Inc.

ALMS

Alumis Inc.